explore -WSS

explore

author：knowledge 2025-09-04 22:03:01 - browse：2375

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： The surgeon had a dilemma only a Nazi medical text could resolve

focus

WSS

ALS treatment from Biogen, Ionis fails in study

Dewpoint Therapeutics lays off staff after losing partnerships

Why doctors need education on FDA device approval process

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

EU regulator recommends expanding Mounjaro approval to obesity

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

hotspot

explore

focus

Hollywood unions extend contract negotiations for actors

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

23andMe had bad news about my health. I wish a person had delivered it

Parkinson’s finding may lead to tests and, someday, treatments

Drug repurposing or repositioning? The language matters

EU regulator recommends expanding Mounjaro approval to obesity

Virginia high school admissions case could be legal follow

The White House hikes tariffs on plastic syringes made in China

As demand for Covid shots wanes, Moderna seeks its next success

NIH director takes cautious approach to Biden drug pricing priority

focus

Readout Newsletter: Merck, J&J, and long Covid

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

STAT reporters are Pulitzer Prize finalists for investigative reporting

The surgeon had a dilemma only a Nazi medical text could resolve

The tragedy of Johnson & Johnson’s Covid vaccine

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

focus

hotspot

focus

explore